A generic medicine reaches the market without repeating the large trials that established the original product's effect. Instead it must demonstrate bioequivalence, a narrower comparison that rests on a specific piece of reasoning. What follows describes the regulatory concept, not guidance about switching any particular medication, which is a conversation for a prescriber or pharmacist.
The original evidence is not re-created
When a brand-name drug is approved, its maker has shown through controlled trials that the compound produces a clinical effect at a given dose with an acceptable safety profile.
That finding belongs to the molecule rather than to the manufacturer. Once the underlying evidence exists, repeating the trials on a chemically identical compound would expose new participants to risk for no new knowledge.
Regulators therefore allow an abbreviated pathway, on the condition that the copy delivers the same active ingredient to the body in the same way.
Bioequivalence measures blood levels, not symptoms
A bioequivalence study gives healthy volunteers the generic and the reference product on separate occasions and measures the concentration of drug in blood over time.
Two figures come out of that curve: the peak concentration reached, and the total exposure represented by the area under the curve.
If those figures fall within an accepted range of the reference product's values, the products are treated as interchangeable in their effect on the body.
The tolerance range is statistical
The accepted range is applied to a confidence interval around the ratio between products, not to a single average result.
This is stricter than it sounds, because a study with wide variability cannot produce a narrow enough interval to pass even if its average looks close.
The requirement is tightened further for drugs with a narrow margin between an effective and a harmful level, where small differences carry more consequence.
Inactive ingredients can differ
Fillers, binders, dyes and coatings are not required to match, which is why generic tablets often look nothing like the original.
Those differences can matter to individual patients with sensitivities to a particular excipient, even when the active compound is identical.
Anyone who notices a change after a substitution should raise it with a pharmacist rather than assume the products are equivalent for them personally.
Some formulations are harder to copy
Extended-release products depend on a delivery mechanism as much as on the compound, so matching blood levels requires reproducing a release profile rather than a chemical.
Inhalers, injectables and topical products raise similar difficulties, because delivery to the site of action is not captured by a blood measurement alone.
Biologic medicines fall outside the framework entirely. They are produced in living systems and cannot be copied exactly, so they follow a separate pathway with its own comparative testing requirements.